Entrectinib in locally advanced or metastatic ROS1 fusion-positive non-small cell lung cancer (NSCLC): Integrated analysis of ALKA-372-001, STARTRK-1 and STARTRK-2
Year: 2019
Type: article
Abstract: Background: Entrectinib is a potent ROS1 inhibitor (as well as TRKA/B/C), designed to effectively penetrate the central nervous system (CNS); brain metastases are common in patients (pts) with advanced ROS1 fusion-positive NSCLC. Entrectinib achieves therapeutic levels in the CNS with antitumour activity in multiple intracranial tumour models. We present updated integrated safety and efficacy data from three Phase 1/2 entrectinib studies (ALKA-372-001 [EudraCT 2012-000148-88], STARTRK-1 [NCT02097810], STARTRK-2 [NCT02568267]) in pts with locally advanced/metastatic ROS1 fusion-positive NSCLC.
Source: Annals of Oncology
Institutions: Aix-Marseille Université, Assistance Publique Hôpitaux de Marseille, Memorial Sloan Kettering Cancer Center, University of Milan, Fondazione IRCCS Istituto Nazionale dei Tumori, Yonsei Cancer Hospital, Samsung Medical Center, Sungkyunkwan University, Azienda Socio Sanitaria Territoriale Grande Ospedale Metropolitano Niguarda, University of Manchester, The Christie NHS Foundation Trust, National Taiwan University, Olivia Newton-John Cancer Wellness & Research Centre, Austin Health, National Cancer Centre Singapore, National Hospital Organization Kyushu Cancer Center, Gdańsk Medical University, Sarah Cannon Research Institute, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, University Hospital Cologne, Genentech
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $2,250
Funder: Roche
OpenAlex ID: W2939418306